Read by QxMD icon Read


Baris Yilmaz, Serap Teksoz, Ayfer Yurt Kilcar, Eser Ucar, Cigdem Ichedef, Emin Ilker Medine, Kadir Ari
The aim of current study is to examine hydroxyurea (HU), which is an antineoplastic drug used for the treatment of leukemia, sickle-cell disease, HIV, psoriasis, thrombocythemia, and various neoplastic diseases in two aspects. The active ingredient hydroxyurea was obtained by purification of the capsule form drug, commercially named as HYDREA. Then, [(99m)Tc(CO)3](+)core radiolabeling with HU was performed as first aspect. Quality control studies of (99m)Tc(CO)3-HU complex were performed by thin-layer radiochromatography and high-performance liquid radiochromatography methods...
February 2016: Cancer Biotherapy & Radiopharmaceuticals
Pauline Leloup, Pascal Toussaint, Jean-Paul Lembelembe, Philippe Célérier, Hervé Maillard
This study aims to demonstrate the analgesic efficacy of electrostimulation (ES), a recognised treatment for leg ulcers. Patients treated by ES for leg ulcers between 2011 and 2013 were included in the study. The pain score obtained with the numerical rating scale (NRS) was reported before the start of the ES (D0), after 3 days (D3) and 1 week following treatment initialisation. The analgesic treatments (AT) were reported at each assessment. Seventy-three patients were included (mean age 75·19 years): 31 venous leg ulcers, 21 mixed venous leg ulcers, 2 arterial ulcers, 17 hypertensive ischaemic ulcers, 1 Hydrea(®)-induced ulcer and an amputation stump ulcer...
December 2015: International Wound Journal
Aurelia Tatic, Mariana Vasilică, Adriana Coliţă, Didona Vasilache, Camelia Dobrea, Cerasela Jardan, Amelia Maria Găman, Ana Manuela Crişan, D Coliţă, D Coriu
In the WHO classification, there is a provisional entity called Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/MPN, U). Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) was included in this category. Recently published studies report a small percentage of patients with RARS-T. Sixty percent of these have JAK2 V617F mutation, which can suggest the coexistence of two pathological conditions (MDS and MPN). In this paper, we analyzed three patients diagnosed with RARS-T in the Department of Hematology, "Fundeni" Clinical Institute, Bucharest, Romania, during the period 2005-2011...
2013: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
M Dooms, H Pincé, S Simoens
WHAT IS KNOWN AND OBJECTIVE: Orphan drugs are used to diagnose, prevent or treat a rare disease. This Commentary aims to present a number of case studies questioning the need for designating compounded medications with a long history of effective use, which is well-supported by published clinical evidence. COMMENT: Prior to the market introduction of orphan drugs, medication compounding was done in our hospital pharmacy for several rare diseases. Examples include amifampridine for the treatment of Lambert-Eaton myasthenic syndrome (Firdapse(®)), ibuprofen for the treatment of neonatal patent ductus arteriosus (Pedea(®)) and zinc acetate for the treatment of Wilson's disease (Wilzin(®))...
February 2013: Journal of Clinical Pharmacy and Therapeutics
Fredrik Tholander, Britt-Marie Sjöberg
Ribonucleotide reductase (RNR) catalyzes reduction of the four different ribonucleotides to their corresponding deoxyribonucleotides and is the rate-limiting enzyme in DNA synthesis. RNR is a well-established target for the antiproliferative drugs Gemzar and Hydrea, for antisense therapy, and in combination chemotherapies. Surprisingly, few novel drugs that target RNR have emerged, partly because RNR activity assays are laboratory-intense and exclude high-throughput methodologies. Here, we present a previously undescribed PCR-based assay for RNR activity measurements in microplate format...
June 19, 2012: Proceedings of the National Academy of Sciences of the United States of America
D De Forni, M R Stevens, F Lori
BACKGROUND AND PURPOSE: Antiviral hyper-activation-limiting therapeutic agents (AV-HALTs) are a novel experimental drug class designed to both decrease viral replication and down-regulate excessive immune system activation for the treatment of chronic infections, including human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome. VS411, a first-in-class AV-HALT, is a single-dosage form combining didanosine (ddI, 400 mg), an antiviral (AV), and hydroxyurea (HU, 600 mg), a cytostatic agent, designed to provide a slow release of ddI to reduce its maximal plasma concentration (C(max)) to potentially reduce toxicity while maintaining total daily exposure (AUC) and the AV activity...
October 2010: British Journal of Pharmacology
Suthat Liangpunsakul, Rong Qi, David W Crabb, Frank Witzmann
OBJECTIVE: The misuse of alcohol, even at levels just above two drinks per day, is a public health problem, but identifying patients with this potentially unhealthy drinking is hindered by the lack of tests. Several blood tests, such as those testing for gamma-glutamyl transpeptidase (GGT) or mean corpuscular volume (MCV), are among the commonly used markers to identify very heavy drinking, but combinations of these markers have rarely been tested in lighter drinkers. We examined the relationship between alcohol drinking and the levels of these markers in a national population-based study composed primarily of lighter drinkers...
March 2010: Journal of Studies on Alcohol and Drugs
Muhammad Irfan, Khalil Hashmi, Salman Adil, Tahir Shamsi, Tasneem Farzana, Saquib Ansari, Vinodh Panjwani, Pervaiz Ahmed, Badshah Khan
OBJECTIVE: To compare PBSCT with BMT in Thalassaemia patients in terms of rejection, non-rejection mortality, disease free survival and overall survival. METHODS: Fifty six patients were transplanted from September 2000 - July 2005. Twenty nine underwent BMT and 27 received PBSCT. Most patients were intensely transfused to keep minimum haemoglobin of 12 gm/dl and received desferioxamine, 24 hours infusion, before transplantation. Pesaro class I (n-20) and class II (n-20) received conditioning with standard Bu/Cy...
March 2008: JPMA. the Journal of the Pakistan Medical Association
Iu A Riabikin, E T Nikitina, A S Balgimbatva, O V Zashkvara, S Sh Shakiev
The fungus Fusarium bulbigenum var. blasticola in which secondary tumor-like formations appear under certain conditions in aging was used as a new test system to examine the action of antitumor preparations. Free radicals in the primary mycelium and tumor-like formations without introduction of preparations (control samples) and after the introduction of preparation into the cultivation medium of the fungus have been studied by EPR spectroscopy. The EPR spectra of the fungus represent single, somewhat asymmetrical lines with a width of deltaH = 0...
March 2007: Biofizika
P Le Nouail, V Viseux, G Chaby, A Billet, J P Denoeux, C Lok
BACKGROUND: Imatinib (Gleevec) is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia. We describe a case of drug reaction with eosinophilia and systemic symptoms (DRESS) after institution of treatment with imatinib. PATIENT AND METHODS: A 78-year-old woman was treated with low-dose imatinib for chronic myeloid leukemia since November 2003. A macular and pruritic eruption appeared on the patient's trunk after 7 weeks of treatment and gradually worsened...
August 2006: Annales de Dermatologie et de Vénéréologie
K Ozawa
Since STI571, a BCR-ABL tyrosine kinase inhibitor, has made a great therapeutic advance in the management of CML, we have to reconsider the treatment protocol for chronic phase CML. Interferon-alpha (IFN-alpha) will be replaced with STI571 therapy. However, some patients are reported to become refractory to STI571, and it is unclear whether STI571 therapy alone may be sufficient to induce long-term survival in CML. There are also important progress in the field of allogeneic hematopoietic stem cell transplantation (SCT); i...
December 2001: Nihon Rinsho. Japanese Journal of Clinical Medicine
B Baker
No abstract text is available yet for this article.
September 1998: Positively Aware: the Monthly Journal of the Test Positive Aware Network
C G Brunstein, P B McGlave
Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to CML have been developed that increase the options available to newly diagnosed patients, and that can cure or prolong survival in this formerly incurable disease. Newly diagnosed patients presenting with extreme leukocytosis or thrombocytosis may benefit from immediate therapy with hydroxyurea (Hydrea) and pheresis...
January 2001: Oncology (Williston Park, NY)
B Wolach, R Gavrieli, Y Manor, M Lishner
The myeloproliferative disorders (MPD) are clonal diseases that originate from a transformed stem cell and involve all myeloid lineage. The affected cells have both proliferative and functional impairment. Therefore, we evaluated and compared neutrophil function in 31 patients with polycythemia vera (PV), idiopathic myelofibrosis (MF), chronic myeloid leukemia (CML), and essential thrombocytosis (ET). Neutrophil chemotaxis, random migration, bactericidal activity and superoxide anion release in these patients were simultaneously compared to those of 31 healthy controls...
December 1998: Blood Cells, Molecules & Diseases
M Goodman, N Spector, G Rodrigues, P A Cassileth
Chronic myeloid leukemia (CML) is usually treated with either alpha-interferon or hydrea. Median survival is 6 years. Eventually, in most CML patients, the disease evolves to blast phase with clinical and morphologic characteristics of an acute leukemia. This phase is commonly associated with systemic symptoms and the appearance of new cytogenetic abnormalities. Therapy for this phase is of limited value, resulting in a mean survival of 4 months. We describe four consecutive patients seen at our clinic with advanced stage CML (three blast, one accelerated phase) who were treated with interleukin-2 (Proleukin)...
November 1998: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
E Estève, M Roger, P Nguyen, B Kalis
No abstract text is available yet for this article.
1996: Annales de Dermatologie et de Vénéréologie
J L Perrot, F Cambazard
No abstract text is available yet for this article.
1994: Annales de Dermatologie et de Vénéréologie
(no author information available yet)
No abstract text is available yet for this article.
September 6, 1968: Medical Letter on Drugs and Therapeutics
(no author information available yet)
No abstract text is available yet for this article.
January 1969: Clinical Pharmacology and Therapeutics
I M Ariel
No abstract text is available yet for this article.
1974: Journal of Surgical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"